Advances in Systemic Therapy for Non-Small Cell Lung Cancer, An Issue of Thoracic Surgery Clinics

1st Edition, Volume 30-2 - May 5, 2020
Editors: Jessica Donington, Jyoti Patel
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 7 9 1 8 9 - 2
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 7 9 1 8 8 - 5

This issue of Thoracic Surgery Clinics, guest edited by Drs. Jyoti Patel and Jessica Donington, is devoted to Advances in Systemic Therapy for Non-Small Cell Lung Cancer. Drs.… Read more

Advances in Systemic Therapy for Non-Small Cell Lung Cancer, An Issue of Thoracic Surgery Clinics

Purchase options

Info / Buy

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

This issue of Thoracic Surgery Clinics, guest edited by Drs. Jyoti Patel and Jessica Donington, is devoted to Advances in Systemic Therapy for Non-Small Cell Lung Cancer. Drs. Patel and Donington have assembled expert authors to review the following topics: Adjuvant and Neoadjuvant Immunotherapy; Combining Immunotherapy with Radiation in Lung Cancer; Adjuvant Chemotherapy; ALK Mutations; Molecular Targets Beyond the Big 3; Advances in Systemic Therapy; Liquid Biopsies in NSCLC; Combining Immunotherapy and Chemotherapy for NSCLC; ROS-1 Mutations; EGFR Mutations; and more!

Cover image
Title page
Table of Contents
Copyright
Contributors
Forthcoming Issues
Erratum
Preface
Current Landscape of Personalized Therapy
Key points
Introduction
Immunotherapy
Molecular targeted agents
Epidermal growth factor receptor mutations
Anaplastic lymphoma kinase mutations
Rare mutations
Summary
Epidermal Growth Factor Receptor Mutations
Key points
Background
Diagnosis
Treatment
Summary
Anaplastic Lymphoma Kinase Mutation–Positive Non–Small Cell Lung Cancer
Key points
Introduction
Diagnostic testing
Tyrosine kinase inhibitors
Tyrosine kinase inhibitors in development
Resistance mechanisms
Systemic therapy after tyrosine kinase inhibitors
Discussion
Future directions
ROS1-rearranged Non–small Cell Lung Cancer
Key points
Introduction
ROS1 molecular basis
ROS1 clinical data
ROS1 resistance mechanisms
Summary
Molecular Targets Beyond the Big 3
Key points
Introduction
B-Raf proto-oncogene
Neurotrophin tyrosine kinase receptor
Kirsten rat sarcoma viral oncogene
Human epidermal growth factor receptor 2
RET proto-oncogene
Mesenchymal-epithelial transition
Neuregulin 1
Summary
Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer
Key points
Introduction
Cell-free DNA
Circulating tumor DNA detection methods
Clinical use of liquid biopsies
Liquid biopsy challenges
Future directions
Summary
Adjuvant Chemotherapy
Key points
Chemotherapy
Immunotherapy
Targeted therapy
Summary
Principles of Immunotherapy in Non-Small Cell Lung Cancer
Key points
Introduction
Clinical data of anti-PD-1/PD-L1 monotherapy in non-small cell lung cancer
Clinical data of immune checkpoint combination therapy in non-small cell lung cancer: dual immunotherapy
Clinical data of immune checkpoint combination therapy in non-small cell lung cancer: immunotherapy/chemotherapy combinations
Future directions
Summary
Combining Immunotherapy and Chemotherapy for Non–Small Cell Lung Cancer
Key points
Introduction: overview of advanced non–small cell lung cancer treatment
Non–small cell lung cancer immunology and the use of checkpoint inhibition
Platinum-based chemotherapy immunomodulation and synergy with immunotherapy
Clinical data combining chemotherapy with immunotherapy in nonsquamous non–small cell lung cancer
Role of immunotherapy in epidermal growth factor receptor and anaplastic large-cell lymphoma kinase mutated non–small cell lung cancer tumors
Trial data combining chemotherapy with immunotherapy in squamous non–small cell lung cancer
Outline of active treatment protocols
Summary
Biomarkers for Immunotherapy
Key points
Introduction
Tumor expression of programmed death-ligand 1 by immunohistochemistry
Tumor mutational burden
Microsatellite instability and mismatch repair–deficient cancers
Tumor lymphocyte infiltration
Multiomics prediction model for immune checkpoint inhibitor response
Mutational status
STK11/LKB1
Smoking history
Human leukocyte antigen class I
Future directions
Adjuvant and Neoadjuvant Immunotherapy in Non–small Cell Lung Cancer
Key points
Checkpoint blockade in metastatic non–small cell lung cancer
Checkpoint blockade in locoregional non–small cell lung cancer
Adjuvant checkpoint blockade
Rationale for neoadjuvant checkpoint blockade
Existing evidence for neoadjuvant checkpoint blockade
Ongoing studies examining neoadjuvant checkpoint blockade
Neoadjuvant immunoradiation
Summary and future directions
Combining Immunotherapy with Radiation Therapy in Non–Small Cell Lung Cancer
Key points
Introduction
Radiation in non–small cell lung cancer
Immune checkpoint blockade
The intersection of radiation and immunotherapy
Radiation and immunotherapy in metastatic non–small cell lung cancer
Radiation and immunotherapy in locally advanced non–small cell lung cancer
Radiation and immunotherapy in early-stage non–small cell lung cancer
Future direction and summary